Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT01455701
- Locations
- 🇺🇸
Hackensack University Medical Center; Pediatric Rheumatology, Hackensack, New Jersey, United States
🇺🇸Children's National Medical Center; Pediatric Rheumatology, Washington, District of Columbia, United States
🇺🇸The Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 296
- Registration Number
- NCT01450696
A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 129
- Registration Number
- NCT01447420
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4442
- Registration Number
- NCT01447446
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 74
- Registration Number
- NCT01442155
A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 177
- Registration Number
- NCT01438749
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: PlaceboDrug: RO4917523 1.5 mgDrug: RO4917523 0.5 mg
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 319
- Registration Number
- NCT01437657
A Study of RG1662 in Individuals With Down Syndrome
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT01436955
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01433575
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1013
- Registration Number
- NCT01429792
- Locations
- 🇮🇱
Holy Family Medical Center; Gastroenterology, Nazareth, Israel
🇮🇱Chaim Sheba Medical Center; Gastroenterology, Ramat Gan, Israel
🇮🇱Maccabi Health Services MC, Tel Aviv, Israel